Comparison of basal insulin glargine (300 units/ml) and degludec (100 units/ml) using continuous glucose monitoring-based time-in-range in type 1 diabetes: the InRange trial

Abstract:

Continuous glucose monitoring (CGM) based time-in-range (TIR) nowadays represents the basis of glucose monitoring, especially in patients with type 1 diabetes (DM1) on intensive insulin therapy. The InRange study compared the second-generation basal insulin analogs, insulin glargine 300 U/ml (Gla-300) and insulin degludec 100 U/ml (IDeg- 100) using TIR as the primary endpoint in adults with DM1. Percentage TIR (glucose level ≥3.9 ≤10 mmol/L) was the primary endpoint and did not differ significantly between the 2 basal insulins and was 52.74% for Gla-300 and 55.09% for IDeg-100. The glucose total coefficient of variation, which was the main secondary endpoint, did not differ significantly between the 2 basal insulins and was 39.91% for Gla-300 and 41.22% for IDeg-100. The InRange study showed that Gla- 300 and IDeg-100 in adults with DM1 have a comparable effect on glycemic control measured with TIR and the glucose total coefficient of variation with a comparable risk of hypoglycemia and similar safety profile.

Key words:
continuous glucose monitoring; degludec; glargine; time-in-range; type 1 diabetes